Danaher Co. (NYSE:DHR) Shares Purchased by Calamos Wealth Management LLC

Calamos Wealth Management LLC increased its holdings in shares of Danaher Co. (NYSE:DHR) by 1,646.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,925 shares of the conglomerate’s stock after purchasing an additional 57,436 shares during the quarter. Danaher makes up approximately 0.7% of Calamos Wealth Management LLC’s portfolio, making the stock its 29th biggest position. Calamos Wealth Management LLC’s holdings in Danaher were worth $13,985,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Wedge Capital Management L L P NC boosted its holdings in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the period. Meridian Financial Partners LLC raised its stake in shares of Danaher by 4.4% during the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after acquiring an additional 40 shares in the last quarter. Kovack Advisors Inc. grew its stake in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the last quarter. Well Done LLC increased its holdings in shares of Danaher by 1.2% during the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after acquiring an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC raised its holdings in shares of Danaher by 0.9% in the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after buying an additional 42 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of NYSE:DHR opened at $214.09 on Tuesday. Danaher Co. has a 1 year low of $214.03 and a 1 year high of $281.70. The business has a fifty day simple moving average of $235.40 and a 200 day simple moving average of $253.09. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm has a market cap of $154.64 billion, a price-to-earnings ratio of 40.55, a P/E/G ratio of 2.80 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the business earned $2.09 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.77 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.45%.

Analyst Ratings Changes

DHR has been the subject of several recent analyst reports. Scotiabank assumed coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. UBS Group cut their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. TD Cowen lifted their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus raised their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Raymond James reaffirmed a “market perform” rating on shares of Danaher in a report on Monday. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.00.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.90% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.